Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors

Trial Profile

Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Erlotinib (Primary) ; Tipifarnib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jan 2014 Planned End Date changed to 1 May 2008 as the status is active, no longer recruiting as reported in ClinicalTrials.gov record.
    • 29 Dec 2006 Status change
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top